文献速递其他结缔组织病

系统性硬化症临床试验终点:专家观点与未来展望

Expert viewpoint on endpoints in systemic sclerosis: current and future outlook.
PubMed 文献 · RMD Open · 2026-07-15

该专家综述探讨系统性硬化症(SSc)临床试验终点现状与未来方向,回顾三类试验设计概念,强调患者报告结局与复合终点的重要性,并指出需纳入时间事件分析、影像和生物标志物以提高敏感性。

要点

  • SSc试验设计分单器官、单器官主要终点联合多系统次要终点、以及明确设计复合终点三类。
  • 患者报告结局如HAQ-DI和ScleroID日益重要,候选复合终点如修订版CRISS整合临床、功能和患者中心指标。
  • 现有终点多在疾病晚期评估损伤,需早期进展指标、时间事件分析、影像和生物标志物。

核心结论

  • SSc临床试验终点需纳入患者报告结局、复合终点及时间事件分析、影像和生物标志物,以提升敏感性和相关性。

研究设计与样本

  • 专家综述,探讨SSc临床试验终点的当前格局与未来方向。

主要发现

  • 历史上SSc试验概念分三类:单器官研究、单器官主要终点联合多系统次要终点提示疾病修饰、以及明确设计复合终点证明疾病修饰。
  • 患者报告结局如HAQ-DI和ScleroID提供患者体验价值。
  • 候选复合终点包括修订版CRISS,整合临床、功能和患者中心测量以更好反映疗效。
  • 许多终点评估晚期损伤,需早期疾病进展指标。
  • 建议纳入时间事件分析、影像和生物标志物评估,并细化复合终点纳入连续测量及血管和胃肠受累等更广域。

临床怎么用

  • 在SSc临床试验中可考虑采用患者报告结局(如HAQ-DI、ScleroID)和复合终点(如修订版CRISS)评估疗效。
  • 关注早期疾病进展指标,并探索时间事件分析、影像和生物标志物在终点中的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Systemic sclerosis (SSc) is a rare, heterogeneous, systemic autoimmune rheumatic disease characterised by vasculopathy, immune dysregulation and fibrosis affecting multiple organ systems. The complexity and variability of SSc manifestations pose significant challenges for clinical trial design and endpoint selection. Historically, three types of trial concepts have emerged: studies focused on a single organ; studies suggesting disease modification by combining a primary single-organ endpoint with supportive secondary endpoints across other systems, and studies explicitly designed to demonstrate disease modification through combined endpoints.This expert review explores the current landscape and future directions of clinical endpoints in SSc trials. It highlights the growing importance of patient-reported outcomes, such as the Health Assessment Questionnaire-Disability Index and ScleroID, which provide valuable insights into patient experiences. The review also discusses the emergence of candidate composite endpoints, including the revised Composite Response Index in Systemic Sclerosis, which integrates clinical, functional and patient-centred measures to better reflect treatment efficacy.Despite progress, significant unmet needs remain. Many endpoints assess damage at advanced stages, underscoring the need for earlier indicators of disease progression. The review advocates for incorporating time-to-event analyses, imaging and biomarker-based assessments to enhance sensitivity and relevance. It also emphasises the importance of refining composite endpoints to include continuous measures and broader domains such as vascular and gastrointestinal involvement. These efforts aim to improve the design and interpretability of SSc clinical trials, ultimately enhancing therapeutic development and patient outcomes.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Hoffmann-Vold AM, Distler O, Del Galdo F, et al. Expert viewpoint on endpoints in systemic sclerosis: current and future outlook. RMD Open. 2026. PMID: 42457218. doi:10.1136/rmdopen-2026-006784

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。